Search
riociguat (Adempas)
Indications:
- FDA-approved to improve exercise capacity in adults with pulmonary hypertension due to
- chronic pulmonary embolism after surgery
- idiopathic pulmonary arterial hypertension
- chronic thromboembolic pulmonary hypertension (CTEPH)
- improves 6 minute walking distance in patients with pulmonary hypertension
Dosage:
- 1.5-2.5 mg PO TID [2]
Adverse effects:
- similar to placebo [1]
- diarrhea, dizziness, dyspepsia, headache, nausea, peripheral edema, vomiting [2]
Mechanism of action:
- stimulates guanylate cyclase, enhances action of nitric oxide
- diminishes pulmonary artery pressure, increase pulmonary perfusion
Interactions
drug adverse effects of antihypertensive agents
General
vasodilator agent
Database Correlations
PUBCHEM cid=11304743
References
- Ghofrani H-A et al.
Riociguat for the treatment of pulmonary arterial hypertension.
N Engl J Med 2013 Jul 25; 369:330
PMID: 23883378
- Ghofrani H-A et al.
Riociguat for the treatment of chronic thromboembolic pulmonary
hypertension.
N Engl J Med 2013 Jul 25; 369:319.
PMID: 23883377
- FDA News Release: Oct. 8, 2013
FDA approves Adempas to treat pulmonary hypertension
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370866.htm